Gri bio reports first quarter 2024 financial results and provides corporate update

Interim data readout of phase 2a biomarker study evaluating lead program gri-0621 for the treatment of idiopathic pulmonary fibrosis (ipf) expected q3 2024 and topline data on track for q4 2024

GRI Ratings Summary

GRI Quant Ranking